Hormonal
Epigenetic silencing of the GLP-1 receptor (GLP-1R) via DNMT3A-mediated hypermethylation impairs incretin signaling and insulin secretion in pancreatic beta-cells.
In Type 2 Diabetes, the body's ability to respond to GLP-1 (a hormone that stimulates insulin) is often turned off by epigenetic silencing of the GLP-1 receptor. This silencing is driven by enzymes like DNMT3A. Understanding this mechanism highlights why therapies that target these epigenetic modifiers or mimic GLP-1 (like GLP-1 agonists) are effective, as they bypass or reverse this specific block in insulin secretion.
DNMT3A induced hypermethylation of glucagon-like peptide-1 receptor (GLP-1R) promoter silences receptor expression thereby reduces GLP-1 driven cAMP/PKA signalling and hence insulin secretion
Why this rating
The paper is a review citing multiple studies on specific gene methylation (PDX1, GLP-1R) and enzyme activity (DNMT3A).
Source
Epigenetic regulation in type II diabetes: linking molecular mechanisms to clinical management
Maryam Chaudhry et al. · Journal of Diabetes & Metabolic Disorders · 2026
DOI 10.1007/s40200-025-01831-1
More from this paper
- Obesity and central adiposity drive insulin resistance and hypertension through the dysregulation of adipokines (elevated TNF-α, IL-6, leptin; reduced adiponectin), which activate inflammatory pathways like NF-κB and RAAS.Strong
- Chronic hyperglycemia and oxidative stress induce beta-cell dedifferentiation by altering the balance of PAX4 and ARX gene expression, causing beta-cells to lose insulin-secreting identity and adopt alpha-cell features.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →